Dr. Parmar is a Principal at 5AM Ventures, a leading life sciences venture capital firm, where he develops investment opportunities, negotiates financings and actively advises portfolio companies. Prior to joining 5AM, he trained at Harvard Medical School, where he was an NIH-sponsored MD/Ph.D. Physician Scientist Trainee in the joint Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals.
Kush Parmar’s Ph.D. work at Harvard unveiled a novel paradigm of how blood flow leads to “healthy” changes in arteries, published in The Journal of Clinical Investigation, Journal of Biological Chemistry and others. In addition, he attended courses at Harvard Business School in private equity and finance and consulted for a Boston area oncology startup.
Kush Parmar holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. Kush Parmar is a Board Observer for Achaogen, Atterocor, Cleave Biosciences, Envoy Therapeutics, Novira Therapeutics and Pulmatrix.